Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) was the target of a large decline in short interest in August. As of August 14th, there was short interest totaling 42,400 shares, a decline of 77.5% from the July 30th total of 188,339 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.
Shanghai Junshi Biosciences Price Performance
SHJBF stock opened at C$3.35 on Friday. The stock’s 50 day simple moving average is C$3.35 and its 200 day simple moving average is C$3.19. Shanghai Junshi Biosciences has a fifty-two week low of C$2.99 and a fifty-two week high of C$4.23.
Shanghai Junshi Biosciences Company Profile
Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.
Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.
See Also
- Five stocks we like better than Shanghai Junshi Biosciences
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
